FILING ANALYSIS · WEDNESDAY, NOVEMBER 18
Retension Pharmaceuticals, Inc. RTSN — 8-K: Results of Operations and Financial Condition
negative
The company's recent IPO generated $51.75 million in gross proceeds, which will be used to complete the Phase 2b clinical trial of RTN-001 and prepare for Phase 3, but the filing also shows a significant decrease in cash position from $18.9 million to $9.2 million as of September 30, 2026, before the IPO proceeds
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →